Qureshi Sana, Elliott Ryan B, Herrington Jon D
1 Scott & White Memorial Hospital, Department of Pharmacy, Baylor Scott & White Health, Temple, TX, USA.
2 Scott & White Memorial Hospital, Department of Radiology, Baylor Scott & White, Temple, TX, USA.
J Oncol Pharm Pract. 2017 Dec;23(8):625-628. doi: 10.1177/1078155216667637. Epub 2016 Sep 7.
Bevacizumab is an important component in the treatment of metastatic colorectal cancer when used with 5-fluorouracil, leucovorin and oxaliplatin or irinotecan. As a molecular target agent, it is considered to be less toxic than traditional chemotherapy; however, bevacizumab has been shown to cause serious, life-threatening adverse effects. The following report describes a case of bevacizumab-associated pulmonary embolism with simultaneous gastrointestinal perforation in a patient with stage IV adenocarcinoma of the descending colon. This case report and literature review describes the risk factors, etiology, and typical presentation of bevacizumab-induced gastrointestinal perforation and pulmonary embolism.
贝伐单抗与5-氟尿嘧啶、亚叶酸钙和奥沙利铂或伊立替康联合使用时，是转移性结直肠癌治疗中的重要组成部分。作为一种分子靶向药物，它被认为比传统化疗毒性更小；然而，贝伐单抗已被证明会引起严重的、危及生命的不良反应。以下报告描述了1例降结肠癌IV期患者发生贝伐单抗相关肺栓塞并同时伴有胃肠道穿孔的病例。本病例报告及文献综述描述了贝伐单抗诱发胃肠道穿孔和肺栓塞的危险因素、病因及典型表现。
